Intrinsa

RSS

Withdrawn

This medicine's authorisation has been withdrawn

testosterone
MedicineHumanWithdrawn

Dutch is available via eTranslation, the European Commission's machine translation service.

Translate to Dutch | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On 28 July 2006 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Intrinsa (testosterone). Intrinsa is approved for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy. The Marketing Authorisation Holder (MAH) responsible for Intrinsa was Warner Chilcott UK Ltd. 

The European Commission was notified by letter dated 13 March 2012 of the MAH’s decision to voluntarily withdraw the marketing authorisation for Intrinsa for commercial reasons. On 25 May 2012 the European Commission issued a decision to withdraw the marketing authorisation for Intrinsa.

Pursuant to this decision the European Public Assessment Report for Intrinsa is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (291.39 kB - PDF)

Bekijk

español (ES) (224.65 kB - PDF)

Bekijk

čeština (CS) (266.63 kB - PDF)

Bekijk

dansk (DA) (243.36 kB - PDF)

Bekijk

Deutsch (DE) (225.77 kB - PDF)

Bekijk

eesti (ET) (223.17 kB - PDF)

Bekijk

ελληνικά (EL) (298.11 kB - PDF)

Bekijk

français (FR) (225.04 kB - PDF)

Bekijk

italiano (IT) (225.26 kB - PDF)

Bekijk

latviešu (LV) (270.17 kB - PDF)

Bekijk

lietuvių (LT) (250.28 kB - PDF)

Bekijk

magyar (HU) (262.07 kB - PDF)

Bekijk

Malti (MT) (265.74 kB - PDF)

Bekijk

Nederlands (NL) (223.92 kB - PDF)

Bekijk

polski (PL) (263.45 kB - PDF)

Bekijk

português (PT) (224.53 kB - PDF)

Bekijk

română (RO) (249.31 kB - PDF)

Bekijk

slovenčina (SK) (265.91 kB - PDF)

Bekijk

slovenščina (SL) (261.6 kB - PDF)

Bekijk

suomi (FI) (223.94 kB - PDF)

Bekijk

svenska (SV) (239.94 kB - PDF)

Bekijk

Product information

български (BG) (776.04 kB - PDF)

Bekijk

español (ES) (375.27 kB - PDF)

Bekijk

čeština (CS) (620.46 kB - PDF)

Bekijk

dansk (DA) (521.26 kB - PDF)

Bekijk

Deutsch (DE) (394.85 kB - PDF)

Bekijk

eesti (ET) (374.96 kB - PDF)

Bekijk

ελληνικά (EL) (830.64 kB - PDF)

Bekijk

français (FR) (330.76 kB - PDF)

Bekijk

italiano (IT) (324.41 kB - PDF)

Bekijk

latviešu (LV) (703.49 kB - PDF)

Bekijk

lietuvių (LT) (464.98 kB - PDF)

Bekijk

magyar (HU) (613.6 kB - PDF)

Bekijk

Malti (MT) (665.61 kB - PDF)

Bekijk

Nederlands (NL) (381.49 kB - PDF)

Bekijk

polski (PL) (585.39 kB - PDF)

Bekijk

português (PT) (324.27 kB - PDF)

Bekijk

română (RO) (477.78 kB - PDF)

Bekijk

slovenčina (SK) (639.84 kB - PDF)

Bekijk

slovenščina (SL) (604.52 kB - PDF)

Bekijk

suomi (FI) (378.55 kB - PDF)

Bekijk

svenska (SV) (377.35 kB - PDF)

Bekijk

Íslenska (IS) (374.24 kB - PDF)

Bekijk

norsk (NO) (371.26 kB - PDF)

Bekijk
Latest procedure affecting product information:R/0018
25/05/2012
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (172.54 kB - PDF)

Bekijk

español (ES) (115.87 kB - PDF)

Bekijk

čeština (CS) (156.31 kB - PDF)

Bekijk

dansk (DA) (126.77 kB - PDF)

Bekijk

Deutsch (DE) (115.61 kB - PDF)

Bekijk

eesti (ET) (115.83 kB - PDF)

Bekijk

ελληνικά (EL) (126.29 kB - PDF)

Bekijk

français (FR) (115.48 kB - PDF)

Bekijk

italiano (IT) (115.35 kB - PDF)

Bekijk

latviešu (LV) (162.57 kB - PDF)

Bekijk

lietuvių (LT) (156.14 kB - PDF)

Bekijk

magyar (HU) (136.21 kB - PDF)

Bekijk

Malti (MT) (168.15 kB - PDF)

Bekijk

Nederlands (NL) (115.96 kB - PDF)

Bekijk

polski (PL) (139.9 kB - PDF)

Bekijk

português (PT) (115.29 kB - PDF)

Bekijk

română (RO) (154.68 kB - PDF)

Bekijk

slovenčina (SK) (153.89 kB - PDF)

Bekijk

slovenščina (SL) (139.86 kB - PDF)

Bekijk

suomi (FI) (115.27 kB - PDF)

Bekijk

svenska (SV) (115.55 kB - PDF)

Bekijk

Íslenska (IS) (115.41 kB - PDF)

Bekijk

norsk (NO) (116.07 kB - PDF)

Bekijk

Product details

Name of medicine
Intrinsa
Active substance
testosterone
International non-proprietary name (INN) or common name
testosterone
Therapeutic area (MeSH)
Sexual Dysfunctions, Psychological
Anatomical therapeutic chemical (ATC) code
G03BA03

Pharmacotherapeutic group

Sex hormones and modulators of the genital system

Therapeutic indication

Intrinsa is indicated for the treatment of hypoactive sexual desire disorder (HSDD) in bilaterally oophorectomised and hysterectomised (surgically induced menopause) women receiving concomitant estrogen therapy.

Authorisation details

EMA product number
EMEA/H/C/000634
Marketing authorisation holder
Warner Chilcott UK Ltd.

Old Belfast Road
Milbrook
Larne
County Antrim
BT40 2SH
United Kingdom

Marketing authorisation issued
28/07/2006
Withdrawal of marketing authorisation
25/05/2012
Revision
6

Assessment history

This page was last updated on

Share this page